GlassScriptPhysician profile
Juliana J Grey
NPI 1750355640
$3,077.34
in general payments reported to CMS, 2019-2025
31 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $225 · 2021: $416 · 2022: $310 · 2023: $511 · 2024: $750 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.01 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $311.51 | 2019-2025 | Hyqvia, Entyvio, Glassia |
| Janssen Biotech, INC. | $245.73 | 2019-2024 | Stelara, Simponi Aria, Remicade |
| Genentech USA, INC. | $237.72 | 2020-2025 | Ocrevus, Ocrevus Zunovo, Xolair |
| Glaxosmithkline, LLC. | $184.18 | 2020-2024 | Nucala |
| Alexion Pharmaceuticals, INC. | $165.31 | 2023-2024 | Ultomiris, Soliris |
| Genzyme Corporation | $151.12 | 2019-2022 | |
| Amgen INC. | $144.66 | 2021-2025 | Evenity, Uplizna, Prolia |
| Horizon Therapeutics Plc | $140.81 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $120.44 | 2019-2023 | Keytruda |
| Daiichi Sankyo INC. | $119.59 | 2020-2024 | Injectafer |
| Allergan, INC. | $109.80 | 2019-2020 | |
| Eisai INC. | $102.96 | 2024 | |
| Tg Therapeutics, INC. | $94.82 | 2024 | |
| Alnylam Pharmaceuticals INC. | $87.22 | 2019-2024 | Onpattro |
| Sanofi-Aventis U.S. LLC | $84.96 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $71.49 | 2022-2023 | Tezspire |
| Grifols USA, LLC | $70.89 | 2023-2024 | Gamunex-C |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.56 | 2022-2023 | Spevigo |
| Lilly USA, LLC | $65.49 | 2024-2025 | Omvoh, Kisunla |
| Fresenius Kabi USA, LLC | $65.27 | 2024 | Idacio |
| Pfizer INC. | $62.65 | 2020-2023 | |
| Pharmacosmos Therapeutics INC. | $54.83 | 2023-2024 | Monoferric |
| Biogen, INC. | $52.65 | 2021 | |
| Shire North American Group INC | $51.24 | 2019 | |
| Argenx US, INC. | $47.34 | 2025 | Vyvgart Hytrulo, Vyvgart |
| E.R. Squibb & Sons, L.L.C. | $43.51 | 2020-2021 | |
| Lundbeck LLC | $41.77 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $22.57 | 2025 | |
| Abbvie INC. | $22.31 | 2025 | |
| Organon LLC | $20.90 | 2023 | Renflexis |
| Teva Pharmaceuticals USA, INC. | $15.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juliana Grey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.